Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | SVP, Chief Scientific Officer | March 15, 2013 | March 19, 2013 |
| CHIMERIX INCCMRX · Entity 80651 | Director | June 28, 2017 | June 29, 2017 |
| IQVIA HOLDINGS INC.IQV · Entity 3058 | Director | April 23, 2026 | April 27, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director · President and CEO | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date March 15, 2013 · Filed March 19, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.01 par valueSEC Table I · non-derivative | Direct | 107,320 |
Ending reported balance
After 2013-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2013-03-15 · Exercise / conversion · Acquired 46,700 · Balance 154,020 Row 2 · 2013-03-15 · Sale · Disposed 46,700 · Balance 107,320 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.86 · Expires 2018-02-14 | Direct | 46,700 |
Reported balance
After 2013-03-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2013-03-15 · Exercise / conversion · Disposed 46,700 · Balance 46,700 |
| Common stock, $0.01 par valueSEC Table I · non-derivative | IndirectProfit sharing trust | 6,473 |
Reported balance
Holding disclosure · report date 2013-03-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,473 F1: Balance in the AbbVie Savings Program as of March 15, 2013. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the AbbVie Savings Program as of March 15, 2013.
CHIMERIX INC
Report date June 28, 2017 · Filed June 29, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2027-06-27 | Direct | 21,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 21,000 · Balance 21,000 F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting.
IQVIA HOLDINGS INC.
Report date April 23, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,946 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Grant · Acquired 1,571 · Balance 16,946 F1: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant.
Intellia Therapeutics, Inc.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,147,064 |
Ending reported balance
After 2026-08-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-20 · Sale · Disposed 19,890 · Balance 1,149,849 F1: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price. Row 2 · 2026-08-21 · Sale · Disposed 2,785 · Balance 1,147,064 F1: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 58,415 |
Reported balance
Holding disclosure · report date 2026-08-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 58,415 F3: Shares held by the John M. Leonard 2015 Irrevocable Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price.
F3: Shares held by the John M. Leonard 2015 Irrevocable Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vitae Pharmaceuticals, Inc
Report date October 25, 2016 · Filed October 25, 2016
Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.85 · Expires 2025-07-28 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-10-25 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2: This option, which provided for vesting in equal quarterly installments over three years following July 29, 2015, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
F2: This option, which provided for vesting in equal quarterly installments over three years following July 29, 2015, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
F3: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2020 Filed May 8, 2020 21:07 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | GrantCommon Stock | 1,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001478242-20-000033 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,744 F1 · shares: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:30 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $13.40 | $0.00 |
DisclosureSEC source: 0000899243-20-006979 · doc4.xml · derivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2030-03-01 F1 · derivative.exercise_date: This option was granted on March 2, 2020 with respect to 340,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:33 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $64.52 | $0.00 |
DisclosureSEC source: 0001478242-19-000043 · edgar.xml · derivative · entry 8 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2026-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:33 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $64.86 | $0.00 |
DisclosureSEC source: 0001478242-19-000043 · edgar.xml · derivative · entry 7 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,600 shares Expires 2025-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:33 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,600 | $0.00 Strike: $64.93 | $0.00 |
DisclosureSEC source: 0001478242-19-000043 · edgar.xml · derivative · entry 6 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,600 shares Expires 2025-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:33 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | SaleCommon Stock | 10,100 | $155.00 | $1,565,500.00 |
DisclosureSEC source: 0001478242-19-000043 · edgar.xml · nonDerivative · entry 5 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,252 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:33 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | SaleCommon Stock | 10,100 | $151.00 | $1,525,100.00 |
DisclosureSEC source: 0001478242-19-000043 · edgar.xml · nonDerivative · entry 4 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,352 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:33 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | Exercise / conversionCommon Stock | 7,000 | $64.52 | $451,640.00 |
DisclosureSEC source: 0001478242-19-000043 · edgar.xml · nonDerivative · entry 3 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:33 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | Exercise / conversionCommon Stock | 6,600 | $64.86 | $428,076.00 |
DisclosureSEC source: 0001478242-19-000043 · edgar.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:33 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | Exercise / conversionCommon Stock | 6,600 | $64.93 | $428,538.00 |
DisclosureSEC source: 0001478242-19-000043 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:17 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | GrantCommon Stock | 1,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001478242-19-000030 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,252 F1 · shares: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:21 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-18-063660 · doc4.xml · derivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2028-12-17 F1 · derivative.exercise_date: This option was granted on December 18, 2018 with respect to 240,000 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 14, 2018 Filed May 16, 2018 00:43 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 8,400 | $24.00 | $201,600.00 |
DisclosureSEC source: 0001209191-18-030361 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · price: The shares were sold pursuant to a Rule 10b5-1 trading plan. All shares were sold at $24.00. F2 · ownership.nature: Shares sold by the John Leonard Defined Benefit Pension Plan and Trust. Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 20:31 UTC | IQVIA HOLDINGS INC. IQV · Entity 3058 | GrantCommon Stock | 2,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001478242-18-000033 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,774 F1 · shares: Shares acquired from award of IQVIA Holdings Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 20:32 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $22.78 | $0.00 |
DisclosureSEC source: 0001209191-18-005806 · doc4.xml · derivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: This option was granted on January 25, 2018 with respect to 220,000 shares of Common Stock, with 25% vesting on January 25, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 21:08 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 72,500 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001209191-17-065662 · doc4.xml · derivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2027-12-11 F1 · derivative.exercise_date: This option was granted on December 12, 2017 with respect to 72,500 shares of Common Stock, with 25% vesting on December 12, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 28, 2017 Filed Jun 29, 2017 16:19 UTC | CHIMERIX INC CMRX · Entity 80651 | GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $5.53 | $0.00 |
DisclosureSEC source: 0001209191-17-042284 · doc4.xml · derivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2018 annual stockholder meeting. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 11:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 600 | $12.09 | $7,254.00 |
DisclosureSEC source: 0001209191-17-037512 · doc4.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · Director · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 8,400 F1 · ownership.nature: Shares acquired and held by the John Leonard Defined Benefit Pension Plan and Trust. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 11:55 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 7,800 | $12.06 | $94,068.00 |
DisclosureSEC source: 0001209191-17-037512 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 7,800 F1 · ownership.nature: Shares acquired and held by the John Leonard Defined Benefit Pension Plan and Trust. Read SEC document |
| May 23, 2017 Filed May 25, 2017 20:54 UTC | IQVIA HOLDINGS INC. Q · Entity 3058 | GrantCommon Stock | 2,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001478242-17-000030 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,702 F1 · shares: Shares acquired from award of Quintiles IMS Holdings, Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document |
| January 06, 2017 Filed Jan 11, 2017 01:07 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-17-003286 · doc4.xml · derivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2027-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2017 with respect to 95,000 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 16:34 UTC | Vitae Pharmaceuticals, Inc VTAE · Entity 181526 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | $11.38 Strike: $9.62 | $113,800.00 |
DisclosureSEC source: 0001104659-16-151948 · a4.xml · derivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-05-25 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3 · derivative.exercise_date: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 16:34 UTC | Vitae Pharmaceuticals, Inc VTAE · Entity 181526 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | $11.15 Strike: $9.85 | $223,000.00 |
DisclosureSEC source: 0001104659-16-151948 · a4.xml · derivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-07-28 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2 · derivative.exercise_date: This option, which provided for vesting in equal quarterly installments over three years following July 29, 2015, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 18:46 UTC | CHIMERIX INC CMRX · Entity 80651 | SaleCommon Stock | 5,000 | $5.03 | $25,162.50 |
DisclosureSEC source: 0001209191-16-141878 · doc4.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By John M Leonard TTEE John M Leonard Revocable Trust DTD 12/14/92 Disclosed balance after: 0 F1 · price: The range of sale prices received is $5.03 to $5.035. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. F2 · ownership.direct: 4,000 shares held by Reporting Person were inadvertently reported on the prior Form 4 as held directly. Instead an aggregate of 5,000 shares previously reported on Form 4 were held by the Reporting Person indirectly in the name of his trust. Read SEC document |
| March 15, 2013 Filed Mar 19, 2013 21:13 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 46,700 | $0.00 Strike: $28.86 | $0.00 |
DisclosureSEC source: 0001179110-13-005449 · edgar.xml · derivative · entry 4 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,700 Underlying: Common stock · 46,700 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2013 Filed Mar 19, 2013 21:13 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 46,700 | $38.45 | $1,795,615.00 |
DisclosureSEC source: 0001179110-13-005449 · edgar.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,320 Read SEC document |
| March 15, 2013 Filed Mar 19, 2013 21:13 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 46,700 | $28.86 | $1,347,892.76 |
DisclosureSEC source: 0001179110-13-005449 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2013 Filed Mar 12, 2013 21:08 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 23,644 | $37.50 | $886,650.00 |
DisclosureSEC source: 0001179110-13-004964 · edgar.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,320 Read SEC document |
| March 08, 2013 Filed Mar 12, 2013 21:08 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 4,305 | $37.58 | $161,781.90 |
DisclosureSEC source: 0001179110-13-004964 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,964 Read SEC document |
| February 28, 2013 Filed Mar 4, 2013 22:07 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 9,407 | $36.73 | $345,519.11 |
DisclosureSEC source: 0001179110-13-004010 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,269 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 00:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 7,982 | $37.58 | $299,963.56 |
DisclosureSEC source: 0001179110-13-003025 · edgar.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,676 Read SEC document |
| February 19, 2013 Filed Feb 21, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 29,650 | $0.00 Strike: $27.29 | $0.00 |
DisclosureSEC source: 0001179110-13-003277 · edgar.xml · derivative · entry 4 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,650 Underlying: Common stock · 29,650 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2013 Filed Feb 21, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 25,345 | $37.58 | $952,465.10 |
DisclosureSEC source: 0001179110-13-003277 · edgar.xml · nonDerivative · entry 2 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,981 Read SEC document |
| February 19, 2013 Filed Feb 21, 2013 22:04 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon stock, $0.01 par value | 29,650 | $27.29 | $809,267.10 |
DisclosureSEC source: 0001179110-13-003277 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:04 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 62,020 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-13-003025 · edgar.xml · derivative · entry 4 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,020 Underlying: Common stock · 62,020 shares Expires 2023-02-13 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 20,674 on 02/14/2014, 20,673 on 02/14/2015, and 20,673 on 02/14/2016. Read SEC document |
| February 14, 2013 Filed Feb 20, 2013 00:04 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 30,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003025 · edgar.xml · nonDerivative · entry 1 LEONARD JOHN M. · CIK 0001563584 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,658 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.